EBMT 2023 | Outcomes of patients with B-ALL treated with inotuzumab and who have undergone alloSCT
David Marks, MBBS, PhD, FRACP, FRCPath, University Hospitals Bristol NHS Trust, Bristol, UK, shares the 4-year results of a study evaluating the outcomes of patients with B-cell precursor acute lymphoblastic leukemia (B-ALL) who received inotuzumab ozogamicin and proceeded to allogeneic stem cell transplantation (alloSCT), commenting on the non-relapse mortality rate (NRM), and the incidence and factors associated with veno-occlusive disease (VOD). This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Pfizer, Kite
